modakafusp alfa (TAK-573)

P1/2, N=272, Terminated, Takeda | Completed --> Terminated; Terminated by the sponsor for strategic reasons

P1, N=15, Terminated, Takeda | Completed --> Terminated; Due to strategic reasons (no safety concerns).

P1/2, N=15, Terminated, Takeda | Completed --> Terminated; After completion of Phase 1 Dose Escalation of this study the sponsor decided not to proceed with Phase 2a due to strategic reasons. Thus, no participants were enrolled for Phase 2a and the study was terminated early.

P1/2, N=45, Terminated, Takeda | Completed --> Terminated; Study was terminated early due to futility.

P1, N=15, Completed, Takeda | Trial primary completion date: Jan 2024 --> Jun 2024

P1/2, N=272, Completed, Takeda | Trial primary completion date: Feb 2024 --> Jul 2024

P1/2, N=272, Completed, Takeda | Active, not recruiting --> Completed

P1/2, N=15, Completed, Takeda | Active, not recruiting --> Completed | N=58 --> 15 | Trial completion date: Mar 2025 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2024

P1, N=15, Completed, Takeda | Active, not recruiting --> Completed | N=120 --> 15

P1, N=120, Active, not recruiting, Takeda | Trial completion date: Jan 2028 --> Jun 2024 | Trial primary completion date: Jul 2025 --> Jan 2024

Venetoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor with activity in patients with t(11;14) and/or Bcl-2 expression. Iberdomide and mezigdomide are cereblon E3 ligase modulators with higher potency, immunomodulatory, and antiproliferative activity compared with lenalidomide and pomalidomide...Modakafusp alfa is an immunocytokine that targets interferons to CD38+ cells. It has demonstrated single agent activity in relapsed/refractory MM in the phase 1 setting.

P1/2, N=336, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting